

Resource Summary Report

Generated by [NIF](#) on Aug 30, 2026

NOD.Cg-Prkdc^{scid}/J

RRID:IMSR_JAX:001303

Type: Organism

Proper Citation

RRID:IMSR_JAX:001303

Organism Information

URL: <https://www.jax.org/strain/001303>

Proper Citation: RRID:IMSR_JAX:001303

Description: Mus musculus with name NOD.Cg-Prkdc^{scid}/J from IMSR.

Species: Mus musculus

Synonyms: NOD SCID. NOD.CB17-Prkdc/J

Notes: gene symbol note: hemolytic complement|protein kinase; DNA activated; catalytic polypeptide; mutant strain: Hc|Prkdc

Affected Gene: hemolytic complement|protein kinase; DNA activated; catalytic polypeptide

Genomic Alteration: deficient|severe combined immunodeficiency

Catalog Number: JAX:001303

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: NOD.Cg-Prkdc^{scid}/J

Record Creation Time: 20250513T053625+0000

Record Last Update: 20260829T044914+0000

Ratings and Alerts

- Used for genotyping by the Human Islet Research Network community. Contact(s): [Peter Buchwald](mailto:Peter.Buchwald@hirnetwork.org) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for NOD.Cg-Prkdc^{scid}/J.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 655 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Kanei T, et al. (2026) Suppressive effects on metastasis and tumor growth by the knockout of chemokine receptors in a canine cutaneous lymphoma model. The Journal of veterinary medical science, 88(1), 104.

Bhandari N, et al. (2026) MRPL47 deficiency drives mitochondrial dysfunction via ROS-p38-p21 signaling in non-small cell lung cancer. The Journal of biological chemistry, 302(2), 111058.

Khan UK, et al. (2026) DKC1 promotes colorectal cancer progression and therapy resistance by dysregulating sphingolipid biosynthesis. Nature communications, 17(1).

Huang Y, et al. (2026) Oral AZD5438 is a clinically translatable otoprotectant against cisplatin-induced hearing loss. Neoplasia (New York, N.Y.), 71, 101250.

Kreig JAF, et al. (2026) The decay of HIV under anti-retroviral therapy is biphasic even in humanized mice with just T cells. Journal of virology, 100(2), e0132125.

Fabilane CS, et al. (2026) Miniaturized IL-2/anti-IL-2 immunocytokines selectively activate and support the in vivo persistence of regulatory T cells. Frontiers in immunology, 17, 1755812.

Roy J, et al. (2026) Synthetic Immunological Niche Reveals Early Immune Dysregulation and Stratifies Therapeutic Response in Type 1 Diabetes. bioRxiv : the preprint server for biology.

Raj R R, et al. (2026) EPHA2-Ephrin-B1 cis-interaction drives an oncogenic reverse signaling, leading to the recurrence of oral cancer. Cell communication and signaling : CCS, 24(1).

Imori K, et al. (2026) Loss of Brg1 and Pten in Pancreatic Ductal Cells Forms Intraductal Tubulopapillary Neoplasm via the YAP/TAZ Pathway. Cellular and molecular gastroenterology and hepatology, 20(2), 101639.

DiLisio JE, et al. (2026) Antigen-specific immunotherapy with a CD4+ T cell neoepitope restrains CD8+ T cell differentiation in murine pancreatic islet grafts. *Nature communications*, 17(1).

Akaike Y, et al. (2026) Generation of a HiBiT-expressing recombinant rat hepatitis virus supporting both in vivo and in vitro infection. *PLoS pathogens*, 22(4), e1014127.

Lee SG, et al. (2026) Targeting IP6 signaling to destabilize homologous recombination proteins to overcome PARP inhibitor resistance. *Nature communications*, 17(1).

Jing Y, et al. (2026) Increased Nur77 is disconnected from TCR affinity in insulin-specific Tregs. *Journal of immunology (Baltimore, Md. : 1950)*, 215(6).

Sugiyama G, et al. (2026) Vascular Endothelial Growth Factor Receptor 2-Targeted Therapy Suppresses the Progression of Alpha-Fetoprotein-Positive Hepatocellular Carcinoma After Combination Therapy With Anti-Programmed Death-Ligand 1 and Anti-Vascular Endothelial Growth Factor-A Antibodies. *Gastro hep advances*, 5(1), 100778.

Angom RS, et al. (2026) Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme. *Communications medicine*, 6(1).

Ohashi T, et al. (2026) ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer. *Cancer research communications*, 6(2), 421.

Monavarian M, et al. (2026) Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition. *JCI insight*, 11(4).

Feng Q, et al. (2026) Targeting severe acidity for tumor-activatable Interleukin-2 therapy. *Cell reports. Medicine*, 7(1), 102572.

Kiliti AJ, et al. (2026) An AIB1 isoform rewires glucocorticoid receptor signaling to promote TNBC progression. *iScience*, 29(2), 114768.

Enriquez JR, et al. (2026) Messenger RNA delivery to islet ?? cells using conjugated lipid nanoparticles. *Cell reports. Medicine*, 7(3), 102634.